☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
ObsEva
ObsEva’s Yselty (linzagolix) Receive EC's Marketing Authorization for the Treatment of Uterine Fibroids
June 20, 2022
ObsEva Reports Efficacy Results of Linzagolix in the P-III (EDELWEISS 3) Trial for the Treatment of Endometriosis-Associated Pain
March 23, 2022
ObsEva Entered into a License Agreement with Theramex to Commercialize Linzagolix for Uterine Fibroids and Endometriosis -Associat...
February 11, 2022
PharmaShots Weekly Snapshots (January 03 - 07, 2021)
January 7, 2022
ObsEva Reports Results of Linzagolix in P-III (EDELWEISS 3) Trial for the Treatment of Endometriosis-Associated Pain
January 7, 2022
Load more...
Back to Home
Modal title
×
Modal body text goes here.